S&P 500 Consumer Staples Sector SEC Filings — October 21, 2026

Q3 2026 net revenues up 5.5% (7.1% organic) to $11.4B and operating income up 14.1% (10.5% organic) to a record quarterly level, with international combustibles growth of 6.5% driven by 8.9% pricing

Japan HTU adjusted IMS grew 3.4% (1.3% excluding pantry-loading ahead of the October 1 JPY20 excise-driven price increase) with IQOS category share held at 68%, showing resilient share in a key market

Full-year adjusted diluted EPS guidance narrowed to $8.29-$8.44 (9.9%-11.9% growth), with the low end of the range still implying double-digit growth

Adjusted diluted EPS grew only 5.4% to $2.36 versus operating income growth of 14.1%, indicating below-the-line or share-count drag that narrows the earnings conversion of top-line gains

Management now signals a greater likelihood of lower-half operating income growth due to geopolitical cost pressures and increased U.S. ZYN investment, a clear shift in second-half tone

U.S. ZYN operating companies income declined 3.3% reported (up only 1.5% organically) as commercial investment rose significantly, signaling that ZYN profitability is being traded for growth

International combustibles growth benefited from a favorable distribution-term restructuring not expected to recur at the same level, so underlying growth is lower than the 6.5% headline

Reported diluted EPS declined 4.9% to $2.12 on a non-cash fair value adjustment; the gap versus adjusted EPS is non-operational and should be discounted for run-rate analysis

10% owner trust sold 7,865 shares at $167.22 (~$1.32M) across 9 transactions, reducing holdings to 536,119 shares

Sales were executed under a Rule 10b5-1 plan, so the selling reflects a pre-set diversification schedule rather than a discretionary view on the stock, limiting its signal strength

Trade prices clustered tightly between $166.97 and $168.53 across tranches, showing orderly execution around the mid-$160s level

Adjusted EPS growth of 5.4% trails operating income growth of 14.1%, and reported EPS fell 4.9% on a non-cash fair value adjustment, creating a wide gap between headline and recurring earnings

Management shifted to a greater likelihood of lower-half operating income growth, a softening that could pressure the consensus EPS range of $8.29-$8.44

Significantly higher U.S. ZYN commercial investment cut ZYN operating companies income 3.3% reported, and only 1.5% organically, so the market is paying for growth that has not yet shown up in profit

International combustibles growth included a distribution-term restructuring benefit not expected to recur at the same level, creating a base-effect headwind into future quarters

Management cited geopolitical cost pressures as a driver of the lower-half operating income skew, a risk outside direct company control that may persist

Japan HTU growth of 3.4% fell to 1.3% excluding pantry-loading ahead of the October 1 JPY20 excise price increase, so reported volume momentum is partly timing-driven

The 10% owner trust reduced its stake by roughly 1.3M dollars of stock across 9 transactions, a negative directional signal even though it is plan-driven

8.9% international combustibles pricing combined with a 14.1% operating income gain points to durable pricing power that can continue to support margin expansion if volumes hold

IQOS category share held at 68% in Japan despite the October 1 JPY20 excise-driven price increase, showing resilient franchise economics in a key profit pool

Narrowed adjusted EPS guidance of $8.29-$8.44 keeps the floor at 9.9% growth, so downside risk is bounded by a credible double-digit earnings base if management delivers

Heavy U.S. ZYN commercial spending is a deliberate investment in category leadership; if organic ZYN income growth (1.5% now) inflects, the earnings drag reverses and supports upside to the EPS range

The reported EPS decline is driven by a non-cash fair value adjustment, so a reversal of that charge would lift reported EPS toward the $2.36 adjusted run-rate

Because the trust sells under a Rule 10b5-1 plan, the sales are mechanically scheduled and not a signal of insider view, so the stock can be evaluated on fundamentals without a conviction discount

Philip Morris reported 8.9% pricing in international combustibles and organic net revenue growth of 7.1%, showing that staples leaders still lean on price to drive growth even as volume recovery is uneven (Japan volume growth ex-pantry-loading only 1.3%)

Heavy commercial investment, notably in U.S. ZYN where operating companies income fell 3.3% reported, is being prioritized over near-term profit, a pattern consistent with staples management teams reinvesting in growth categories and pressuring operating leverage

Adjusted EPS grew 5.4% while reported EPS fell 4.9% on non-cash items, reinforcing the need to underwrite staples earnings on normalized numbers and to scrutinize fair value adjustments and one-time distribution benefits

The pantry-loading ahead of Japan's October 1 excise-driven price increase illustrates how regulatory tax changes distort quarterly volume and reported growth across tobacco and nicotine categories, complicating near-term comparisons

The Hershey trust's 10b5-1 sales highlight that much of staples insider activity is systematic diversification rather than conviction signals, so insider filings should be weighted lower than discretionary trades in this sector

Test whether the narrowed $8.29-$8.44 adjusted EPS guidance holds given the stated lower-half operating income skew; date to be confirmed against the next scheduled release

Monitor whether ZYN organic operating income (up 1.5%) inflects positively as commercial investment matures; key data point for the next quarterly report

Track HTU and IQOS share after the October 1 JPY20 excise-driven price increase to assess whether the 1.3% underlying growth rate holds once pantry-loading unwinds

Watch for management updates on the geopolitical cost headwinds cited as a driver of lower-half operating income growth, which could widen the guidance range

Monitor international combustibles revenue in upcoming quarters as the non-recurring distribution-term benefit rolls off, which will reveal true underlying growth

Track whether the 10% owner trust continues its 10b5-1 sales program and how the remaining 536,119 shares are disposed of over subsequent Form 4 filings